Lipoprotein lipase activator NO-1886 (ibrolipim) accelerates the mRNA expression of fatty acid oxidation-related enzymes in rat liver

This publication has 13 references indexed in Scilit:

• The role of uncoupling proteins in pathophysiological states
  Biochemical and Biophysical Research Communications, 2002
• Genetic and physiological analysis of the role of uncoupling proteins in human energy homeostasis.
  Journal of Molecular Medicine, 2000
• The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet
  Diabetologia, 2000
• The actions of a novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats
  Metabolism, 1998
• Antiatherogenic Effects of a Novel Lipoprotein Lipase-Enhancing Agent in Cholesterol-Fed New Zealand White Rabbits
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity
  Metabolism, 1997
• Mammalian mitochondrial β-oxidation
  Biochemical Journal, 1996
• Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats
  Diabetes, 1995
• Relationship between skeletal muscle lipoprotein lipase activity and 24-hour macronutrient oxidation.
  Journal of Clinical Investigation, 1993
• The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.
  Journal of Clinical Investigation, 1993